Recently, French pharmaceutical giant Sanofi announced that its new drug for treating hypertriglyceridemia, pemafibrate, has been approved by China’s National Medical Products Administration (NMPA). Pemafibrate is a highly selective PPAR-alpha agonist designed to lower triglyceride levels in patients with severe hypertriglyceridemia, thereby reducing the risk of complications such as pancreatitis.Hypertriglyceridemia is a common lipid disorder, with rising prevalence in China—particularly among individuals with obesity or diabetes. Traditional therapies like statins have limited efficacy in lowering triglycerides, and existing fibrate-class drugs raise concerns regarding liver and kidney safety. As a next-generation fibrate, pemafibrate demonstrates higher receptor selectivity, greater lipid-lowering potency, and favorable safety and tolerability profiles in clinical trials.The approval was supported by data from multiple international and China-specific clinical studies, including a Phase III trial conducted locally. Results showed that pemafibrate reduced triglyceride levels by over 40% with a low incidence of adverse events. Experts believe this new treatment will offer Chinese patients a more effective and safer therapeutic option, addressing an unmet clinical need in managing severe hypertriglyceridemia.
近日，法国制药巨头赛诺菲（Sanofi）宣布其用于治疗高甘油三酯血症的新药——佩玛贝特（Pemafibrate）已获得中国国家药品监督管理局（NMPA）批准上市。该药物是一种高选择性PPAR-α激动剂，旨在降低严重高甘油三酯血症患者的甘油三酯水平，从而减少胰腺炎等并发症风险。高甘油三酯血症是一种常见的血脂异常疾病，在中国患病率呈上升趋势，尤其在肥胖和糖尿病人群中更为普遍。传统治疗手段如他汀类药物对甘油三酯的降低效果有限，而现有贝特类药物存在肝肾安全性顾虑。佩玛贝特作为新一代贝特类药物，具有更高的受体选择性和更强的降脂效力，同时在临床试验中展现出良好的安全性和耐受性。此次获批基于多项国际及中国本地临床研究数据，包括在中国开展的III期临床试验，结果显示佩玛贝特可显著降低患者甘油三酯水平达40%以上，且不良反应发生率较低。业内专家认为，该药的上市将为中国高甘油三酯血症患者提供更有效、更安全的治疗选择，填补当前临床治疗空白。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/9632.html